Doximity, which ranks fifth on the IBD 50, crushed December-quarter expectations late Thursday and raised its outlook for the ...
Dynatrace has climbed above the buy point from a cup-without-handle base, but the history of its chart suggests some caution.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback